Paris (AP) – A Paris court will rule on Monday in a case that has turned into one of France’s biggest health scandals to decide whether the French pharmaceutical company is guilty of murder and other counts of selling anti-diabetic drugs, which have killed hundreds. ,
Servier Laboratories, accused of taking advantage of patients’ lives, faces millions of euros in fines and damages after a huge lawsuit involving 6,500 plaintiffs. They claim that the company allowed a drug called “Mediator” to be widely and irresponsibly prescribed as a diet pill with deadly effects. Servier says he did not know about the risks of the drug.
The exclusive trial lasted from September 2019 to July 2020, with a two-month break due to the coronavirus epidemic. It was distributed in five rooms of the Paris courthouse, which were connected by video. Nearly 400 lawyers worked on the case.
Servier was convicted of murder, involuntary manslaughter, fraud, embezzlement and other charges. The investigating judges concluded that the server had been covering the mediator’s patients’ illnesses for decades. The French National Agency for Drugs is also suspected of collaborating to cover up the dangers of drugs.
Prosecutors demanded a fine of about 15 million euros (about $ 18 million) for Servier, և three years in prison և 278,000 euros in fines for the only executive director accused in the case, Dr. Jean an Philippe Seta.
In addition, 6,500 plaintiffs are claiming a total of 1 billion euros in damages.
Servier’s lawyers argued that the company was not aware of the risks associated with Mediator until 2009. They asked for a verdict of acquittal.
During 33 years of being in the broker market, according to 2010 According to the study, up to 2,000 deaths were suspected among millions of people who took it as an appetite suppressant. Doctors linked it to the heart and lungs.
One doctor noted the concerns back in 1998 and testified that he had been persecuted for taking them back. Faced with side effects from Swiss, Spanish and Italian medical authorities, Servier removed it from those markets between 1997 and 2004.
It led to an independent investigation by another concerned French doctor before the company ceased sales in its main market in France in 2009. It was not sold in the United States.
The company’s CEO և founder ques ak Servier was indicted at the start of the trial, but he died in 2014.